All In Biotech

Drug Trial Radar · NCT07134465

Clinical Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HSK31858 in Healthy Subjects

A Single-center, Open-label, Two-period, Fixed-sequence Clinical Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HSK31858 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

24

Planned (sponsor's estimate)

Start

Aug 11, 2025

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, two-period, fixed-sequence clinical study to evaluate the effect of Itraconazole on the pharmacokinetics of HSK31858 in healthy subjects

Conditions

  • Healthy Subjects

Interventions

  • HSK31858 Tablets and Itraconazole CapsulesDrug

    HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered. Itraconazole capsules After a 10-day washout period, Take Itraconazole capsules 200mg in the morning and 200mg in the evening on D11 . A single dose of Itraconazole capsules 200 mg will be administered every morning from Day 12 to Day 14. On the morning of Day 15, take a single dose of itraconazole capsules 200mg, followed by a single dose of HSK31858 tablets 40 mg 1 hour later,

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: [Time Frame: From the start of administration to 216 hours post-dose]
  2. AUC(0-∞)Time frame: [Time Frame: From the start of administration to 216 hours post-dose]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.